<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">6741602</PMID>
      <DateCompleted>
        <Year>1984</Year>
        <Month>08</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>08</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0001-690X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>69</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>1984</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta psychiatrica Scandinavica</Title>
          <ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Trihexyphenidyl dependence.</ArticleTitle>
        <Pagination>
          <StartPage>538</StartPage>
          <EndPage>542</EndPage>
          <MedlinePgn>538-42</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Trihexyphenidyl, a synthetic anticholinergic, is frequently used concurrently with neuroleptics to control extrapyramidal side effects. We present two case reports of trihexyphenidyl abuse which concur with the increasing concern expressed regarding the abuse potential of trihexyphenidyl. In one of the cases a double-blind, placebo-controlled withdrawal was conducted and monitored on a number of physiological parameters and the Hamilton Anxiety Rating Scale. A recognizable withdrawal syndrome followed discontinuation of the drug. In addition to the abuse potential it is suggested that dependence liability be considered in maintenance therapy with trihexyphenidyl and other antiparkinsonians.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McInnis</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Petursson</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Acta Psychiatr Scand</MedlineTA>
        <NlmUniqueID>0370364</NlmUniqueID>
        <ISSNLinking>0001-690X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>6RC5V8B7PO</RegistryNumber>
          <NameOfSubstance UI="D014282">Trihexyphenidyl</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014282" MajorTopicYN="Y">Trihexyphenidyl</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1984</Year>
          <Month>6</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1984</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1984</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">6741602</ArticleId>
        <ArticleId IdType="doi">10.1111/j.1600-0447.1984.tb02528.x</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
